Mn Services Vermogensbeheer B.V. Sells 6,300 Shares of Danaher Co. (NYSE:DHR)

Mn Services Vermogensbeheer B.V. trimmed its position in shares of Danaher Co. (NYSE:DHR) by 2.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 277,500 shares of the conglomerate’s stock after selling 6,300 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Danaher were worth $69,333,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Cape Investment Advisory Inc. acquired a new stake in Danaher in the 4th quarter worth approximately $25,000. Tsfg LLC lifted its stake in Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. acquired a new stake in Danaher in the 2nd quarter valued at approximately $25,000. Redmont Wealth Advisors LLC acquired a new stake in Danaher in the 1st quarter valued at approximately $30,000. Finally, Richardson Financial Services Inc. acquired a new stake in Danaher in the 4th quarter valued at approximately $42,000. 79.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Royal Bank of Canada boosted their target price on shares of Danaher from $297.00 to $300.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. SVB Leerink boosted their price target on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. TD Cowen upped their target price on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. The Goldman Sachs Group increased their price target on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Finally, Robert W. Baird upped their price objective on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Six research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $276.88.

Danaher Stock Up 0.6 %

DHR traded up $1.65 during trading on Friday, reaching $269.48. 1,464,013 shares of the stock were exchanged, compared to its average volume of 2,820,898. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The stock’s 50 day moving average price is $258.72 and its two-hundred day moving average price is $254.38. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The stock has a market cap of $199.60 billion, a P/E ratio of 45.67, a price-to-earnings-growth ratio of 4.62 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the previous year, the firm earned $2.05 earnings per share. Danaher’s revenue for the quarter was down 2.9% compared to the same quarter last year. Equities analysts expect that Danaher Co. will post 7.59 EPS for the current year.

Insider Buying and Selling

In other news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. The disclosure for this sale can be found here. Insiders have sold a total of 38,707 shares of company stock worth $10,786,944 in the last ninety days. Corporate insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.